Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Inhibrx Biosciences, Inc.

Healthcare US INBX

91.25USD
-3.97(4.17%)

Last update at 2026-06-04T20:00:00Z

Day Range

91.0395.59
LowHigh

52 Week Range

14.3039.79
LowHigh

Fundamentals

  • Previous Close 95.22
  • Market Cap1800.01M
  • Volume264376
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-248.02400M
  • Revenue TTM1.78M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM -107.99400M
  • Diluted EPS TTM-5.48

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -145.22300M -81.76600M -75.63400M -50.50200M -30.92500M
Minority interest - - - 0.00000M -0.14200M
Net income -145.22600M -81.76800M -75.63700M -51.40000M -31.16300M
Selling general administrative 21.12M 12.36M 6.84M 9.02M 4.65M
Selling and marketing expenses - - - - -
Gross profit 2.18M 7.12M 12.81M 9.09M 8.60M
Reconciled depreciation 1.23M 1.20M 1.02M 1.16M 0.68M
Ebit -130.34200M -77.75900M -68.46200M -43.71400M -29.44500M
Ebitda -129.11700M -76.56400M -67.44300M -42.60400M -28.76900M
Depreciation and amortization 1.23M 1.20M 1.02M 1.11M 0.68M
Non operating income net other 0.00100M 0.01M 2.14M - -
Operating income -129.11700M -76.56400M -67.44300M -43.71400M -29.51300M
Other operating expenses 131.29M 83.69M 80.25M 52.81M 37.01M
Interest expense 16.11M 5.22M 10.82M 5.72M 1.48M
Tax provision 0.00300M 0.00200M 0.00300M 0.90M 0.10M
Interest income - - - - -
Net interest income -16.10700M -5.21600M -10.81600M -5.71900M -1.48000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00300M 0.00200M 0.00300M 0.90M 0.10M
Total revenue 2.18M 7.12M 12.81M 9.09M 7.50M
Total operating expenses 131.29M 83.69M 80.25M 52.81M 37.01M
Cost of revenue - - - - -1.09500M
Total other income expense net -16.10600M -5.20200M -8.19100M -6.78800M 0.07M
Discontinued operations - - - - -
Net income from continuing ops -145.22600M -81.76800M -76.12400M -51.40000M -31.02100M
Net income applicable to common shares -145.22600M -81.76800M -76.12400M -51.40000M -31.16300M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 307.89M 290.88M 150.45M 143.74M 26.49M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 16.66M 6.63M 7.81M 132.17M 0.38M
Total liab 264.39M 232.82M 98.07M 68.27M 120.06M
Total stockholder equity 43.50M 58.06M 52.38M 75.47M -93.56900M
Deferred long term liab - - - - -
Other current liab 43.30M 17.22M 9.62M 13.36M 4.85M
Common stock 0.00500M 0.00400M 0.00400M 0.00400M 0.00200M
Capital stock 0.00500M 0.00400M 0.00400M 0.00400M 0.00200M
Retained earnings -613.73400M -372.37300M -227.14700M -145.37900M -69.25500M
Other liab - - 0.11M 0.92M 2.92M
Good will - - - - -
Other assets 0.00000M 3.16M 1.85M 0.24M 0.24M
Cash 277.92M 273.87M 131.30M 128.66M 11.54M
Cash and equivalents - - - - -
Total current liabilities 56.31M 27.58M 22.45M 31.40M 20.57M
Current deferred revenue - 0.17M 2.03M 3.08M 7.94M
Net debt -67.78300M -71.79600M -60.83100M -91.21000M 30.19M
Short term debt 2.06M 1.86M 1.67M 1.50M 4.67M
Short long term debt - - - - 3.56M
Short long term debt total 210.14M 202.07M 70.47M 37.45M 41.73M
Other stockholder equity 657.23M 430.43M 279.53M 220.85M -24.31600M
Property plant equipment - 2.50M 9.49M 11.32M 10.68M
Total current assets 295.36M 280.49M 139.11M 132.17M 15.56M
Long term investments - - - - -
Net tangible assets - 58.06M 52.38M 75.47M -93.56900M
Short term investments - - - - -
Net receivables 0.78M 0.26M 0.88M 0.61M 0.44M
Long term debt 206.97M 202.07M 70.47M 29.24M 30.37M
Inventory - -0.25700M -0.87800M -129.27900M 3.21M
Accounts payable 10.95M 8.33M 9.12M 13.46M 3.12M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00000M - -150.45000M -143.74000M -2.38300M
Additional paid in capital - - - - -
Common stock total equity - 0.00400M 0.00400M 0.00400M 0.00200M
Preferred stock total equity - - - - -
Retained earnings total equity - -372.37300M -227.14700M -145.37900M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.16M 3.16M 1.85M 0.24M 0.24M
Deferred long term asset charges - - - - -
Non current assets total 12.53M 10.38M 11.34M 11.57M 10.93M
Capital lease obligations 3.17M 5.03M 6.71M 8.21M 7.80M
Long term debt total - 202.07M 70.47M 29.24M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.68600M -0.80900M -1.36400M -1.81000M -1.42900M
Change to liabilities 6.90M -6.31600M 4.82M 5.46M 4.91M
Total cashflows from investing activities -0.68600M -0.80900M -1.36400M -1.81000M -1.42900M
Net borrowings 128.86M 39.99M 41.35M 33.81M -5.68800M
Total cash from financing activities 258.55M 83.77M 166.46M 43.33M 13.15M
Change to operating activities 5.71M -11.03300M 7.76M -2.47100M -0.11600M
Net income -145.22600M -81.76800M -76.12400M -51.40000M -31.02100M
Change in cash 142.56M 2.64M 117.12M 9.44M -11.36700M
Begin period cash flow 131.30M 128.66M 11.54M 2.10M 13.47M
End period cash flow 273.87M 131.30M 128.66M 11.54M 2.10M
Total cash from operating activities -115.30100M -80.32300M -47.96800M -32.07900M -23.09200M
Issuance of capital stock 127.37M 40.20M 136.85M 12.00M 20.48M
Depreciation 1.23M 1.20M 1.02M 1.16M 0.68M
Other cashflows from investing activities - 0.06M - - -
Dividends paid - - - 0.00000M 0.83M
Change to inventory - -11.03300M 7.76M -2.47100M -0.67200M
Change to account receivables 0.13M -0.16700M 0.12M 0.49M -0.55000M
Sale purchase of stock 129.74M 43.78M 136.88M - -
Other cashflows from financing activities 131.18M 43.57M 35.06M 49.52M 19.67M
Change to netincome 20.47M 16.53M 4.26M 6.41M 2.63M
Capital expenditures 0.69M 0.86M 1.36M 1.81M 1.43M
Change receivables 0.62M -0.13900M -0.17700M - -
Cash flows other operating -2.73600M -7.32600M -4.88900M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes 142.56M 2.64M 117.12M - -
Change in working capital 3.16M -17.51600M 12.69M 3.48M 4.25M
Stock based compensation 20.45M 15.05M 5.02M 3.97M 2.48M
Other non cash items 5.09M 2.73M 11.56M 9.61M 0.52M
Free cash flow -115.98700M -81.18700M -49.33200M -33.88900M -24.52100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
INBX
Inhibrx Biosciences, Inc.		 -3.97 4.17% 91.25 - - 920.99 38.11 883.34 -7.6926
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Inhibrx Biosciences, Inc.

11025 North Torrey Pines Road, La Jolla, CA, United States, 92037

Key Executives

Name Title Year Born
Mr. Mark Paul Lappe Founder, Chairman, Pres & CEO 1967
Dr. Brendan P. Eckelman Ph.D. Founder & Chief Scientific Officer 1979
Ms. Kelly Devine Deck B.S., CPA, M.S. Chief Financial Officer 1980
Mr. Quinn L. Deveraux Founder NA
Dr. Ashraf Amanullah Exec. VP & Chief Technical Operations Officer 1968
Ms. Leah Pollema J.D. VP, Corp. Sec. & Gen. Counsel NA
Mr. Jeffrey J. Jensen EVP & Chief Clinical Devel. Officer NA
Mr. David Matly M.B.A. Exec. VP & Chief Commercial Officer NA
Dr. Carlos Bais Ph.D. Exec. VP of Translational Sciences NA
Mr. Mark Paul Lappe Founder, Chairman, President & CEO 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.